Gilead has said it is exploring a trend towards ... AZ reported the results of the phase 3 LAURA trial of its EGFR inhibitor Tagrisso (osimertinib) in early-stage lung cancer, setting up another ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best humane stocks to invest in now. In recent years, the investment landscape has ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Alnylam Pharmaceuticals (ALNY). But which of these two ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.

**NM signifies a non meaningful value. A dash signifies the data is not available.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...